ABSTRACT
Microsporidiosis is an opportunistic infection in organ transplant recipients and patients with other cellular immunodeficiency. Fumagillin is an effective treatment against Enterocytozoon bieneusi, one of the two main species causing the microsporidiosis involved in human diseases. We report the first case, to our knowledge, of a probable drug-induced aseptic meningoencephalitis, after administration of fumagillin in a kidney transplant recipient with microsporidiosis.
Subject(s)
Antifungal Agents/adverse effects , Cyclohexanes/adverse effects , Fatty Acids, Unsaturated/adverse effects , Kidney Transplantation/adverse effects , Meningoencephalitis/etiology , Microsporidiosis/drug therapy , Cyclohexanes/therapeutic use , Fatty Acids, Unsaturated/therapeutic use , Female , Humans , Immunocompromised Host , Middle Aged , Sesquiterpenes/adverse effects , Sesquiterpenes/therapeutic useABSTRACT
INTRODUCTION: In France, unlike other countries, the use of colchicine is preferred to other anti-inflammatory drugs for the treatment of gout. CASE REPORTS: We report a case series of four elderly patients (range from 72 to 83 years of age) who presented with colchicine intoxication, all notified to the Basse-Normandie pharmacovigilance centre in 2007. For each patient, one or more risk factors were identified: renal failure, high initial dosage, absence of laboratory monitoring. CONCLUSION: It would be useful to establish specific guidelines for colchicine use in the elderly population.